https://www.selleckchem.com/products/hs-10296.html
Based on recent data, the patient was given trabectedin monotherapy as fourth line chemotherapy. He tolerated the therapy well and attained a progression-free survival of 12months, which is an impactful figure in relapsed setting in this patient population. This report aims to present a comprehensive review into available and newer treatment choices for mesenchymal chondrosarcoma, and to highlight trabectedin monotherapy as a possible therapeutic option for mesenchymal chondrosarcoma in the relapsed setting. This report aims to present
Like
Comment
Share
